DNMT1 and diffuse large B-cell lymphoma: Pan H. et al. demonstrated that prolonged exposure to low-dose DNMT inhibitors (DNMTi) reprogrammed chemoresistant GCB- and ABC-DLBCL cells to become doxorubicin sensitive in vivo [417].